Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on February 7, 2006, where the Administrators of the SmithKline Beecham Employee Benefit Trust ("the Trust") transferred 93 Ordinary shares to a participant in the GlaxoSmithKline Annual Investment Plan. This notification was formally communicated to the Company on February 13, 2006.
Management Commentary and Risks
The Trust is described as a discretionary fund where all non-US employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that Director Mr. J Heslop holds an interest in the shares held in the fund in the same capacity as other non-US employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the 93-share transfer.
- Confirm the specific identity of the Annual Investment Plan participant receiving the shares.
- Review the full Disclosure Rule 3.1 4R (1) (b) requirements to ensure complete compliance regarding Director Mr. J Heslop's interest.